Results 81 to 90 of about 175,167 (244)

The m7G Methyltransferase Mettl1 Drives Cardiac Hypertrophy by Regulating SRSF9‐Mediated Splicing of NFATc4

Advanced Science
Cardiac hypertrophy is a key factor driving heart failure (HF), yet its pathogenesis remains incompletely elucidated. Mettl1‐catalyzed RNA N7‐methylguanosine (m7G) modification has been implicated in ischemic cardiac injury and fibrosis.
Shuting Yu, ZhiYong Sun, Tiantian Ju, Yingqi Liu, Zhongting Mei, Changhao Wang, Zhezhe Qu, Na Li, Fan Wu, KuiWu Liu, Meixi Lu, Min Huang, Xiaochen Pang, Yingqiong Jia, Ying Li, Yaozhi Zhang, Shunkang Dou, Jianhao Jiang, Xianhui Dong, Chuanhao Huang, Wanhong Li, Yi zhang, Ye Yuan, Baofeng Yang, Weijie Du   +24 more
doaj   +1 more source

Nuclear receptor corepressor 1 represses cardiac hypertrophy

EMBO Molecular Medicine, 2019
The function of nuclear receptor corepressor 1 (NCoR1) in cardiomyocytes is unclear, and its physiological and pathological implications are unknown. Here, we found that cardiomyocyte‐specific NCoR1 knockout (CMNKO) mice manifested cardiac hypertrophy at
Chao Li, Xue‐Nan Sun, Bo‐Yan Chen, Meng‐Ru Zeng, Lin‐Juan Du, Ting Liu, Hui‐Hui Gu, Yuan Liu, Yu‐Lin Li, Lu‐Jun Zhou, Xiao‐Jun Zheng, Yu‐Yao Zhang, Wu‐Chang Zhang, Yan Liu, Chaoji Shi, Shuai Shao, Xue‐Rui Shi, Yi Yi, Xu Liu, Jun Wang, Johan Auwerx, Zhao V Wang, Feng Jia, Ruo‐Gu Li, Sheng‐Zhong Duan   +24 more
doaj   +1 more source

Biomarkers of lung congestion and injury in acute heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 781-789, April 2025.
Abstract Acute heart failure (AHF) classification and management are primarily based on lung congestion and/or hypoperfusion. The quantification of the vascular and tissue lung damage is not standard practice though biomarkers of lung injury may play a relevant role in this context.
Marco Guazzi, Gabriele Novello, Francesca Bursi, Anna Caretti, Noemi Furlotti, Ross Arena, Paola Argiento, Julio Núñez, Antoni Bayes‐Genis, Marco Metra   +9 more
wiley   +1 more source

The rewiring of cAMP/cGMP and LDH signalling drives cardiac hypertrophy in Pde5a −/− mice

Life Science Alliance
This discovery will be very useful in term of personalized medicine because Pde5a inhibitors should be administrated depending on the severity of cardiac hypertrophy.
Ana Gabriela de Oliveira do Rêgo, Sonia Maccari, Giuseppe Marano, Tonino Stati, Michele Saliola, Mauro Giorgi, Silvia Cardarelli, Matilde Merolle, Francesco Tomassoni-Ardori, Lino Tessarollo, Federica Campolo, Andrea M Isidori, Luciana De Angelis, Fabio Naro, Lucia Monaco, Manuela Pellegrini   +15 more
doaj   +1 more source

Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler, Friederike Zimmermann, Bettina Heidecker, Ulf Landmesser, Arash Haghikia   +4 more
wiley   +1 more source

Fueling Cardiac Hypertrophy [PDF]

Circulation Research, 2020
Timothy R, Matsuura, Teresa C, Leone, Daniel P, Kelly   +2 more
openaire   +2 more sources

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source

Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities

ESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia, Blanche Schroen, Judith M.E.M. Cosemans   +2 more
wiley   +1 more source

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo, Tor Biering‐Sorensen, Joao P. Ferreira, Carlo Mario Lombardi, Andrea Bonelli, Andrea Garascia, Marco Metra, Riccardo M. Inciardi   +7 more
wiley   +1 more source

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley   +1 more source